Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata^1,2

1966 • 2,159 citations

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

1989 • 1,030 citations

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

1988 • 843 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

1989 • 445 citations

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

1996 • 384 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1972 • 315 citations

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1972 • 271 citations

Topoisomerase I inhibitors: topotecan and irenotecan

1994 • 251 citations

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

1996 • 248 citations

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

1996 • 206 citations

Clinical Pharmacokinetics of Topotecan

1996 • 182 citations

Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro

1992 • 174 citations

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

1994 • 166 citations

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

1996 • 149 citations

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

1997 • 139 citations

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

1997 • 137 citations

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

1993 • 135 citations

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1993 • 133 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1996 • 132 citations

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

1996 • 129 citations

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1994 • 127 citations

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1993 • 123 citations

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

1996 • 116 citations

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1992 • 112 citations

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

1996 • 105 citations

Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.

1997 • 100 citations

Phase II study of topotecan in metastatic non-small-cell lung cancer.

1994 • 97 citations

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

1994 • 88 citations

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

1994 • 86 citations

Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function

1996 • 76 citations

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

1997 • 75 citations

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

1995 • 71 citations

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

1997 • 70 citations

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

1996 • 66 citations

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

1997 • 66 citations

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.

1995 • 65 citations

Topoisomerase I Inhibitors: An Overview of the Camptothecin Analogs

1994 • 57 citations

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

1996 • 53 citations

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

1997 • 47 citations

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.

1997 • 45 citations

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

1996 • 44 citations

Phase II trial of topotecan in patients with advanced renal cell carcinoma

1994 • 44 citations

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion

1994 • 43 citations

A Phase II Study of Topotecan in Patients with Recurrent Head and Neck Cancer

1997 • 35 citations

Preclinical and phase I trials of topoisomerase I inhibitors

1994 • 34 citations

Clinical, pharmacokinetic and biological studies of topotecan

1994 • 27 citations

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors

1995 • 27 citations

Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.

1997 • 25 citations

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

1997 • 23 citations

38 Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy

1997 • 21 citations

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1995 • 21 citations

Topotecan, an active new antineoplastic agent: review and current status

1997 • 17 citations

41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC)

1997 • 11 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1994 • 4 citations

Phase I study of paclitaxel (P) combined with 14-day topotecan (T) Continuous IV (CIV) infusion in previously treated and untreated patients (PTS)

1997 • 4 citations

Cited By (0)

No citing papers found in database